Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 4 fois dans les médias — pédagogie reconnue
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
36
36 articles ont été cités au moins 36fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
3 599
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
288
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
80
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Délégation Paris 5 · Université Paris Cité · Assistance Publique – Hôpitaux de Paris
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Comment discriminer les médicaments d’ASMR V : quelles implications et quel parcours d’accès ?
2026ArticleTherapies
How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
2025ArticleTherapies
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
2025ArticleThe Lancet
Methodological expectations for demonstration of health product effectiveness by observational studies
2025ArticleTherapies
Attentes méthodologiques pour la démonstration de l’efficacité des produits de santé par les études observationnelles
2025ArticleTherapies
Controlled human infection trials: Legitimacy and conditions of implementation in France
2024ArticleTherapies
Paediatric drug development and evaluation: Existing challenges and recommendations
2023ArticleTherapies
Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis
2022ArticleJAMA Network Open
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CDS CENTRE MEDICALE ODON VALLET
15 BD DU GAL D'ARMEE JEAN SIMON, 75013 PARIS
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Whatsupdoc-lemag.fr · 15/07/2025
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxONjVBckI2TEFMOVFETlc3QnVSYmtaMVpkZHZ5MmZ1bURzOVpDTFl3NTIwak84Ti1xMW14X0NCcVh1WGd0SkptX2EtMEF6TjEzeWxMUXVOWWsxelJGaWU1Yko0aGxGUHdOWUVQeVRyWTA3aThuQmhVaF9jTloxMHZwV2lGR1ZSNHh4QjFNWnBqVl84WEpFdzJ4NE5UcVhOeVd6cV9GMG1iWmxsaHhSWHFDZ25HOA?oc=5" t
📰 Le Pèlerin · 22/06/2024
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQclZXY29JNktfOXFPTnhwNjJZVl9WVFFqYjIyT1U1N19vcUlDamlFVzVvcGtoZVhxZjIxSkloOGtKQXlRa2g1ZjFLVU1OYUtKWGVORThvdU1YWk81SHUwZ3BwLUhMMXBQX3QwbnhmU282QTJ4R0tFbjFWTDNSOVJseTRLSzdFSVQ1UGxPZ1dpWGo0R1hJM3RyUjBRdlk0bkdwZnJNYkJJZGxVbUpoWUliQmJMLXROWUR0c3
📰 tv5monde · 24/12/2021
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPNm42aDROMGdyOElBRlZoelVpQUlsbndISUlUSkZQMFFkbVhmMndGeFFYeG1naHBqaW5fN2RpRkV5cmdyZTNCZGV3OFNxNnRoRWJFSGtiTkh3VGlPVXRURWxzS0x3Z1VQM2JVV09lVGVaTTBsdmdqSXBFS2FBeEtoSkdLTEtsX1dKWjFkZWEwUUtWRW9Y?oc=5" target="_blank">Dépakine : un nouveau scand
📰 Europe 1 · 02/11/2015
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPbDZnNUlGTkVLWnVCZnlKVDRKQmpqNm9OaWQwSURlTWJTdmE0ZDhESjZkSFlLZnc4X0k3emctb3Y3RUJWZ0NSU01KZUo3Q0c0c0lDRjA1UVZ3VklEOF9wM09TdUxWV0VidXQ3M0I0dms2RGY2dml4ZHpndkNabFBrY0dtbWVJc2oyUjNNZWZ1X0hZenRjUUJhbmR6NnpGdmdzVU5zZktucHlyTnR0elNDUtIBtgFBVV95cU
Arthritis & rheumatology (Hoboken, N.J.) · 2017
ObjectiveIn most patients with nonsevere systemic necrotizing vasculitides (SNVs), remission is achieved with glucocorticoids alone, but one‐third experience a relapse within 2 years. This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN).MethodsAll patients included in this double‐blind trial received glucocorticoids, gradually tapered over 12 months, and were randomized to receive AZA or placebo for 12 months, with stratification according to SNV (EGPA or MPA/PAN). The primary end point was the combined rate of remission induction failures and minor or major relapses at month 24.ResultsNinety‐five patients (51 with EGPA, 25 with MPA, and 19 with PAN) met the inclusion criteria, were randomized, and received at least 1 dose of AZA (n = 46) or placebo (n = 49). At month 24, 47.8% of the patients receiving AZA versus 49% of the patients receiving placebo had remission induction failures or relapses (P = 0.86). Secondary end points were comparable between the AZA and placebo arms. These included initial remission rate (95.7% versus 87.8%), total relapse rate (44.2% versus 40.5%), and glucocorticoid use. Two patients in the placebo arm died; 22 patients in the AZA arm (47.8%) and 23 patients in the placebo arm (46.9%) experienced ≥1 severe adverse event. For EGPA patients, the primary end point (48% in the AZA arm versus 46.2% in the placebo arm) and the percent of patients who experienced asthma/rhinosinusitis exacerbations (24% in the AZA arm versus 19.2% in the placebo arm) were comparable between treatment arms.ConclusionAddition of AZA to glucocorticoids for the induction of remission of nonsevere SNVs does not improve remission rates, lower relapse risk, spare steroids, or diminish the EGPA asthma/rhinosinusitis exacerbation rate.
Rheumatology (Oxford, England) · 2019
Abstract Objective In a previous controlled trial, 1-year adjunction of AZA to glucocorticoids (GC) for patients with non-severe, newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) failed to lower remission failure, vasculitis relapse and isolated asthma/rhinosinus exacerbation rates, or cumulative GC use at month (M) 24. The aim of this study was to analyse longer-term outcomes to determine whether subsequent vasculitis relapse or isolated asthma/rhinosinus exacerbation (IARE) rates differed. Methods After M24, patients were followed prospectively, being treated based on physicians’ best judgment. Flares and reasons for increased GC dose or immunosuppressant use were recorded, and reviewed according to randomization group to distinguish vasculitis relapses from IAREs according to EGPA Task Force recommendations. Results Fifty EGPA trial participants were followed for a median (interquartile range) of 6.3 (5.4–7.6) years; two (4%) died 11 months post-inclusion. By M24, vasculitis had relapsed in 21/49 (43%) patients and 14/50 (28%) had IAREs. Another patient died 4.8 years post-inclusion (infection). Among nine patients with subsequent vasculitis relapses, three had a major relapse and three had their first relapse after M24; among 25 patients with later IAREs, 17 occurred after M24. At 5 years, respective vasculitis relapse and IARE rates were 48% (95% CI 34.0, 62.6) and 56% (95% CI 41.7, 70.8), with no between-arm differences (P = 0.32 and 0.13). No entry clinical or biological parameter was associated with these outcomes during follow-up. Conclusion These results confirmed that 1-year AZA and GC induction obtained good overall survival but no long-term benefit for non-severe EGPA patients. Vasculitis relapses, occurring mostly during the first 2 years, and IAREs, occurring throughout follow-up, require other preventive treatments. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT00647166.
BMC medical education · 2020
Abstract Background The perceived importance of clinical empathy may decline among students during medical training. Several interventions have been shown to be effective in promoting or preserving medical students’ empathic abilities, such as empathy skills training or Balint groups. Although narrative medicine training shares some features with these interventions, no randomized study to date examined the efficacy of narrative medicine training. This study aimed to assess the effects of Balint groups and narrative medicine training on clinical empathy measured by the self-rated Jefferson’s School Empathy Scale - Medical Student (JSPE-MS©) among fourth-year medical students. Methods Students who gave their consent to participate were randomly allocated in equal proportion to Balint groups, narrative medicine training or to the control group. Participants in the intervention groups received either seven sessions of 1.5-h Balint groups or a 2-h lecture and five sessions of 1.5-h narrative medicine training from October 2015 to December 2015. The main outcome was the change in JSPE-MS© score from baseline to one week after the last session. Results Data from 362 out of 392 participants were analyzed: 117 in the control group, 125 in the Balint group and 120 in the narrative medicine group. The change in JSPE-MS© score from baseline to follow-up was significantly higher in the Balint group than in the control group [mean (SD): 0.27 (8.00) vs. -2,36 (11.41), t = 2.086, P = 0.038]. The change in JSPE-MS© score in the narrative medicine group [mean (SD): − 0.57 (8.76)] did not significantly differ from the changes in the control group (t = 1.355, P = 0.18) or the Balint group (t = 0.784, P = 0.43). Adjusting for participants’ characteristics at baseline, Balint groups remained associated with better outcomes compared to the control group (β = 2.673, P = 0.030). Conclusions Balint groups may promote clinical empathy to some extent among medical students, at least in the short run.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
BMC medical education · 2026 · Journal Article
Wolf FI, Trapani V, De Gaetano Donati K, Vlieghe E, et al.
Therapie · 2022 · Journal Article
Gault N, Sallah K, Régent A, Le Jeunne C, et al.
BMC medical education · 2020 · Journal Article
Lemogne C, Buffel du Vaure C, Hoertel N, Catu-Pinault A, et al.
Addiction (Abingdon, England) · 2020 · Letter
Rigal L, Sidorkiewicz S, Le Jeunne C, Porcher R, et al.
Fundamental & clinical pharmacology · 2020 · Journal Article
Larrouquere L, Gabin M, Poingt E, Mouffak A, et al.
Rheumatology (Oxford, England) · 2019 · Journal Article
Puéchal X, Pagnoux C, Baron G, Lifermann F, et al.
ACR open rheumatology · 2019 · Journal Article
Awad F, Assrawi E, Jumeau C, Odent S, et al.
Joint bone spine · 2019 · Letter
Assala M, Groh M, Blanche P, Vinter C, et al.
The American journal of medicine · 2018 · Case Reports
Mageau A, Rodriguez-Régent C, Dion J, Dupin N, et al.
Medical teacher · 2017 · Journal Article
Charlier C, Johannessen I, Mackintosh CL, Wilks D, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
London J, Dumoitier N, Lofek S, Dion J, et al.
Autoimmunity reviews · 2017 · Journal Article
Frumholtz L, Laurent-Roussel S, Aumaître O, Maurier F, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2017 · Journal Article
Puéchal X, Pagnoux C, Baron G, Quémeneur T, et al.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2021 · Journal Article
Dion J, Maisonobe T, Nochy D, Le Jeunne C, et al.
Autoimmunity reviews · 2018 · Journal Article
Paule R, Morel N, Le Guern V, Fredi M, et al.
Arthritis research & therapy · 2018 · Journal Article
Belhocine M, Coutte L, Martin Silva N, Morel N, et al.
Autoimmunity reviews · 2018 · Journal Article
Paule R, Morel N, Le Guern V, Fredi M, et al.
Seminars in arthritis and rheumatism · 2020 · Journal Article
Lauret A, Moltó A, Abitbol V, Gutermann L, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Morel P, Karras A, Porcher R, Belenfant X, et al.
Autoimmunity reviews · 2020 · Journal Article
Chaigne B, Rodeia S, Benmostefa N, Bérézné A, et al.
International journal of cardiology · 2017 · Journal Article
Morel N, Lévesque K, Maltret A, Baron G, et al.
Addiction (Abingdon, England) · 2020 · Journal Article
Rigal L, Sidorkiewicz S, Tréluyer JM, Perrodeau E, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2020 · Journal Article
Terrier B, Dechartres A, Gouya H, Ben Arfi M, et al.
Rheumatology (Oxford, England) · 2021 · Case Reports
Régent A, Terrier B, Legendre P, Wartski M, et al.
Therapie · 2023 · Journal Article
Kaguelidou F, Ouèdraogo M, Treluyer JM, Le Jeunne C, et al.
Vaccine · 2026 · Journal Article
Ranque B, Galtier F, Nunes H, Le Jeunne C, et al.
Survey of ophthalmology · 2021 · Journal Article
Delestre F, Blanche P, Bouayed E, Bouscary D, et al.
Survey of ophthalmology · 2021 · Journal Article
Delestre F, Blanche P, Bouayed E, Bouscary D, et al.
Journal of scleroderma and related disorders · 2021 · Journal Article
Legendre P, Blanchet B, Porcher R, Bérezné A, et al.
Therapie · 2025 · Journal Article
Cucherat M, Demarcq O, Chassany O, Le Jeunne C, et al.
Formation médicale 2011 - Atelier : Le médicament, les vecteurs de sa connaissance . Discussion.
Titre : Formation Médicale 2011 – Atelier : Partage d’expériences : le médicament, les vecteurs de sa connaissance de la formation initiale médicale continueIntervenants : Marc BARDOU (Dijon, CNPM), Claire Le JEUNE (Pari
Formation Médicale 2011 – Les bases thérapeutiques nécessaires à une prescription raisonnée.
Titre : Formation Médicale 2011 – Les bases thérapeutiques nécessaires à une prescription raisonnée.Intervenants : Claire Le JEUNE (Paris, APNET).Résumé : Atelier : Partage d’expériences : le médicament, les vecteurs de
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Joint bone spine · 2017 · Letter
Groh M, Puéchal X, Terrier B, Le Jeunne C, et al.